{"id":"clonazepam-placebo-levetiracetam-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation/drowsiness"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Ataxia"},{"rate":null,"effect":"Behavioral changes"},{"rate":null,"effect":"Respiratory depression (clonazepam)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clonazepam is a benzodiazepine that potentiates GABA-A receptor signaling, increasing chloride influx and neuronal hyperpolarization to suppress seizure propagation. Levetiracetam's exact mechanism remains unclear but involves modulation of synaptic vesicle proteins and neuronal calcium channels. This Phase 3 trial appears to evaluate the comparative efficacy and safety of these agents, likely in acute seizure management or status epilepticus.","oneSentence":"Clonazepam enhances GABAergic inhibition in the central nervous system to reduce seizure activity, while levetiracetam modulates neuronal excitability through an unknown mechanism, and this trial compares clonazepam/placebo with IV levetiracetam.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:24.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute seizure management or status epilepticus (inferred from IV formulation and trial design)"}]},"trialDetails":[{"nctId":"NCT01150331","phase":"PHASE3","title":"Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-07","conditions":"Status; Epilepticus, Tonic-clonic","enrollment":203}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Association of placebo to an active comparator (clonazepam)"],"phase":"phase_3","status":"active","brandName":"Clonazepam/Placebo levetiracetam IV","genericName":"Clonazepam/Placebo levetiracetam IV","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clonazepam enhances GABAergic inhibition in the central nervous system to reduce seizure activity, while levetiracetam modulates neuronal excitability through an unknown mechanism, and this trial compares clonazepam/placebo with IV levetiracetam. Used for Acute seizure management or status epilepticus (inferred from IV formulation and trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}